Currency In USD
| Previous Close | 1.93 |
| Open | 1.99 |
| Day High | 2.21 |
| Day Low | 1.96 |
| 52-Week High | 6.25 |
| 52-Week Low | 1.5 |
| Volume | 25,062 |
| Average Volume | 67,862 |
| Market Cap | 5.08M |
| PE | -0.95 |
| EPS | -2.07 |
| Moving Average 50 Days | 2.23 |
| Moving Average 200 Days | 2.49 |
| Change | 0.04 |
Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
GlobeNewswire Inc.
Feb 10, 2026 2:00 PM GMT
WHO recognition of “etaroleucel” (CELZ-101) builds on prior “olastrocel” (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program executionPHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, I
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
GlobeNewswire Inc.
Jan 13, 2026 2:15 PM GMT
Data Show Strong Functional and Pain Improvements Supported by Excellent Safety ProfilePHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biot
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
GlobeNewswire Inc.
Jan 06, 2026 2:15 PM GMT
PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions,